Diffuse Large B-Cell Lymphoma | Drug Pipeline update.
Roche aims high with Rituxan successor
By Colin White, Lead Analyst
15 August 2013
I am the Lead Analyst for Oncology at Datamonitor Healthcare. I joined Datamonitor in 2009, having previously worked as ...
Read full bio
Review of candidates in development for diffuse large B-cell lymphoma (DLBCL) across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK).
There are currently 25 drugs in development for treatment of DLBCL, including six in Phase III trials.
Phase III drugs are mainly being positioned to satisfy the needs of special patient segments not satisfied by the currently available therapies, especially those for maintenance and second-line therapies.
The huge success gained by the monoclonal antibody (MAb) Rituxan in the DLBCL market is triggering the development of drugs using different selective cell-targeting technologies based on MAbs.
MAb-drug conjugates constitute an emerging trend in chemotherapy for DLBCL as they present the dual advantage of high cell-selectivity and reduced off-target toxicity.
Datamonitor Healthcare has analyzed the DLBCL pipeline, validating pipeline candidates against a variety of sources including BioMedTracker, and company websites.
This is an Oncology analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: